Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Morabito

Showing results (261-270 of 307) with videos related to

Pageof 31
Sort By:
The Cancer Journal From Scientific American|April 13, 1999
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapyG Gasparini, M Toi, R Miceli, et al.
Oncology|October 17, 2002
Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancerS Palmeri, V Leonardi, M Tamburo De Bella, et al.
International Journal of Oncology|April 30, 2011
Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancerS Pignata, R Lauria, F Perrone, et al.
Oncology|November 29, 2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trialS Pignata, G Scambia, A Savarese, et al.
Cancer Research|June 11, 1999
Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell linesP Giacomini, E Giorda, R Fraioli, et al.
Melanoma Research|December 22, 1999
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma)M R Sertoli, P Queirolo, E Bajetta, et al.
Alimentary Pharmacology & Therapeutics|March 25, 2014
Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patientsG D'Amico, L Pasta, A Morabito, et al.
Oncology Reports|May 25, 2011
Cardiovascular monitoring of drug-resistant lymphoma patients treated with epoch chemotherapy plus high-dose verapamil in continuous-infusionP Tagliaferri, P Correale, M Mottola, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|May 10, 2005
Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003E Faglia, L Dalla Paola, G Clerici, et al.
Drugs of Today (Barcelona, Spain : 1998)|October 23, 2010
Vandetanib: An overview of its clinical development in NSCLC and other tumorsA Morabito, M C Piccirillo, R Costanzo, et al.
Pageof 31

Showing results (261-270 of 307) with videos related to

Sort By:
Pageof 31
The Cancer Journal From Scientific American|April 13, 1999
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapyG Gasparini, M Toi, R Miceli, et al.
Oncology|October 17, 2002
Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancerS Palmeri, V Leonardi, M Tamburo De Bella, et al.
International Journal of Oncology|April 30, 2011
Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancerS Pignata, R Lauria, F Perrone, et al.
Oncology|November 29, 2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trialS Pignata, G Scambia, A Savarese, et al.
Cancer Research|June 11, 1999
Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell linesP Giacomini, E Giorda, R Fraioli, et al.
Melanoma Research|December 22, 1999
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma)M R Sertoli, P Queirolo, E Bajetta, et al.
Alimentary Pharmacology & Therapeutics|March 25, 2014
Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patientsG D'Amico, L Pasta, A Morabito, et al.
Oncology Reports|May 25, 2011
Cardiovascular monitoring of drug-resistant lymphoma patients treated with epoch chemotherapy plus high-dose verapamil in continuous-infusionP Tagliaferri, P Correale, M Mottola, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|May 10, 2005
Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003E Faglia, L Dalla Paola, G Clerici, et al.
Drugs of Today (Barcelona, Spain : 1998)|October 23, 2010
Vandetanib: An overview of its clinical development in NSCLC and other tumorsA Morabito, M C Piccirillo, R Costanzo, et al.
Pageof 31